

This Issue

Views **16,257** | Citations **65** | Altmetric **158**



PDF



Full Text



Share



Viewpoint

June 5, 2018

Value-Based Pricing for Drugs Theme and Variations

Anna Kaltenboeck, MA¹; Peter B. Bach, MD²

» [Author Affiliations](#)

JAMA. 2018;319(21):2165-2166. doi:10.1001/jama.2018.4871

In December 2017, the US Food and Drug Administration approved voretigene neparvovec-rzyl (Luxturna), a one-time genetic treatment manufactured by Spark Therapeutics that must be injected into the eye and can improve the vision of individuals with biallelic *RPE65* mutation-associated retinal dystrophy, a rare genetic condition that affects approximately 1000 to 2000 people in the United States each year. The therapy was priced \$850 000 per treatment, just below the million dollar threshold some had anticipated.

 Full Text



Access through your institution

Read More About

Health Care Economics, Insurance, Payment

Pharmacoeconomics

 JAMA+ AI

Others Also Liked